Effect of Yeast-derived β-glucan in Conjunction With Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft Models

摘要: Human lung cancer is the leading cause of death worldwide. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), in combination with chemotherapy showed significant therapeutic efficacy human patients. However, increased adverse effects limit its clinical utilization. Previous studies demonstrated that polysaccharide beta-glucan significantly augments antitumor antibody-mediated via stimulation innate effector neutrophil complement receptor 3. Here, we explored combined bevacizumab therapy for using murine xenograft models. To end, adenocarcinomas were screened membrane-bound VEGF expression. Both subcutaneous and orthotopic models used to evaluate therapy. We found PC14PE6 adenocarcinoma cells express both vitro vivo. Bevacizumab bound surface on activated complement. In tumor model, plus augmented terms progression long-term survival compared bevacizumab-treated alone. These accompanied massive deposition infiltration within tumors. this effect was not observed surface-bound VEGF-negative Therapeutic further an model. Thus, our data suggest enhances bevacizumab-mediated may provide benefits cancers